Rodolfo Daniel Cervantes-Villagrana

Dr. Rodolfo Daniel Cervantes-Villagrana

Pharmacology, University of California San Diego, San Diego, California, USA
orcid
University of California San Diego

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
Rodolfo Daniel Cervantes-VillagranaRodolfo Daniel Cervantes-Villagrana
Rodolfo Daniel Cervantes-Villagrana
DADamaris Albores-García
Damaris Albores-García
ACAlberto Rafael Cervantes-Villagrana
Alberto Rafael Cervantes-Villagrana
SGSara Judit García-Acevez
Sara Judit García-Acevez
Normal cells are hijacked by cancer cells forming together heterogeneous tumor masses immersed in aberrant communication circuits that facilitate tumor growth and dissemination. Besides the well characterized angiogenic effect of some tumor-derived factors; others, such as BDNF, recruit peripheral nerves and leukocytes. The neurogenic switch, activated by tumor-derived neurotrophins and extracellular vesicles, attracts adjacent peripheral fibers (autonomic/sensorial) and neural progenitor cells. Strikingly, tumor-associated nerve fibers can guide cancer cell dissemination. Moreover, IL-1β, CCL2, PGE2, among other chemotactic factors, attract natural immunosuppressive cells, including T regulatory (Tregs), myeloid-derived suppressor cells (MDSCs), and M2 macrophages, to the tumor microenvironment. These leukocytes further exacerbate the aberrant communication circuit releasing factors with neurogenic effect. Furthermore, cancer cells directly evade immune surveillance and the antitumoral actions of natural killer cells by activating immunosuppressive mechanisms elicited by heterophilic complexes, joining cancer and immune cells, formed by PD-L1/PD1 and CD80/CTLA-4 plasma membrane proteins. Altogether, nervous and immune cells, together with fibroblasts, endothelial, and bone-marrow-derived cells, promote tumor growth and enhance the metastatic properties of cancer cells. Inspired by the demonstrated, but restricted, power of anti-angiogenic and immune cell-based therapies, preclinical studies are focusing on strategies aimed to inhibit tumor-induced neurogenesis. Here we discuss the potential of anti-neurogenesis and, considering the interplay between nervous and immune systems, we also focus on anti-immunosuppression-based therapies. Small molecules, antibodies and immune cells are being considered as therapeutic agents, aimed to prevent cancer cell communication with neurons and leukocytes, targeting chemotactic and neurotransmitter signaling pathways linked to perineural invasion and metastasis.

19 March 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
SASuvi Annala
Suvi Annala
XFXiaodong Feng
Xiaodong Feng
NSNaveen Shridhar
Naveen Shridhar
FEFunda Eryilmaz
Funda Eryilmaz
JPJulian Patt
Julian Patt
EKEvi Kostenis
Evi Kostenis
Somatic gain-of-function mutations of GNAQ and GNA11, which encode α subunits of heterotrimeric Gαq/11 proteins, occur in about 85% of cases of uveal melanoma (UM), the most common cancer of the adult eye. Molecular therapies to directly target these oncoproteins are lacking, and current treatment options rely on radiation, surgery, or inhibition of effector molecules downstream of these G proteins. A hallmark feature of oncogenic Gαq/11 proteins is their reduced intrinsic rate of hydrolysis of guanosine triphosphate (GTP), which results in their accumulation in the GTP-bound, active state. Here, we report that the cyclic depsipeptide FR900359 (FR) directly interacted with GTPase-deficient Gαq/11 proteins and preferentially inhibited mitogenic ERK signaling rather than canonical phospholipase Cβ (PLCβ) signaling driven by these oncogenes. Thereby, FR suppressed the proliferation of melanoma cells in culture and inhibited the growth of Gαq-driven UM mouse xenografts in vivo. In contrast, FR did not affect tumor growth when xenografts carried mutated B-RafV600E as the oncogenic driver. Because FR enabled suppression of malignant traits in cancer cells that are driven by activating mutations at codon 209 in Gαq/11 proteins, we envision that similar approaches could be taken to blunt the signaling of non-Gαq/11 G proteins.

27 February 2025 in Cancer Cell
Verified
Journal Article
Closed access
SIMONE LUBRANOSIMONE LUBRANO
SIMONE LUBRANO
Rodolfo Daniel Cervantes-VillagranaRodolfo Daniel Cervantes-Villagrana
Rodolfo Daniel Cervantes-Villagrana
FFFarhoud Faraji
Farhoud Faraji
SRSydney Ramirez
Sydney Ramirez
KSKuniaki Sato
Kuniaki Sato
JGJ.Silvio Gutkind
J.Silvio Gutkind

1 March 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LCLydia Chávez-Vargas
Lydia Chávez-Vargas
SASendi Rafael Adame-García
Sendi Rafael Adame-García
Rodolfo Daniel Cervantes-VillagranaRodolfo Daniel Cervantes-Villagrana
Rodolfo Daniel Cervantes-Villagrana
ACAlejandro Castillo-Kauil
Alejandro Castillo-Kauil
JBJessica G.H. Bruystens
Jessica G.H. Bruystens
JVJOSE VAZQUEZ-PRADO
JOSE VAZQUEZ-PRADO
Morphology of migrating cells is regulated by Rho GTPases and fine-tuned by protein interactions and phosphorylation. PKA affects cell migration potentially through spatiotemporal interactions with regulators of Rho GTPases. Here we show that the endogenous regulatory (R) subunit of type I PKA interacts with P-Rex1, a Rac guanine nucleotide exchange factor that integrates chemotactic signals. Type I PKA holoenzyme interacts with P-Rex1 PDZ domains via the CNB B domain of RIα, which when expressed by itself facilitates endothelial cell migration. P-Rex1 activation localizes PKA to the cell periphery, whereas stimulation of PKA phosphorylates P-Rex1 and prevents its activation in cells responding to SDF-1 (stromal cell-derived factor 1). The P-Rex1 DEP1 domain is phosphorylated at Ser-436, which inhibits the DH-PH catalytic cassette by direct interaction. In addition, the P-Rex1 C terminus is indirectly targeted by PKA, promoting inhibitory interactions independently of the DEP1-PDZ2 region. A P-Rex1 S436A mutant construct shows increased RacGEF activity and prevents the inhibitory effect of forskolin on sphingosine 1-phosphate-dependent endothelial cell migration. Altogether, these results support the idea that P-Rex1 contributes to the spatiotemporal localization of type I PKA, which tightly regulates this guanine exchange factor by a multistep mechanism, initiated by interaction with the PDZ domains of P-Rex1 followed by direct phosphorylation at the first DEP domain and putatively indirect regulation of the C terminus, thus promoting inhibitory intramolecular interactions. This reciprocal regulation between PKA and P-Rex1 might represent a key node of integration by which chemotactic signaling is fine-tuned by PKA.

8 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JGJazbet Gallegos-Bolaños
Jazbet Gallegos-Bolaños
JRJessica Alejandra Rivera-Domínguez
Jessica Alejandra Rivera-Domínguez
JPJosé Miguel Presno-Bernal
José Miguel Presno-Bernal
Rodolfo Daniel Cervantes-VillagranaRodolfo Daniel Cervantes-Villagrana
Rodolfo Daniel Cervantes-Villagrana
Human papillomavirus (HPV) is associated with the genesis of cervical carcinoma. The co-infection among HPV genotypes is frequent, but the clinical significance is controversial; in Mexico, the prevalence and pattern of co-infection differ depending on the geographic area of study. We analyzed the mono- and co-infection prevalence of multiple HPV genotypes, as well as preferential interactions among them in a Mexico City sample population. This study was designed as a retrospective cohort study. Cervical cytology samples from 1163 women and 166 urethral scraping samples of men were analyzed between 2010 and 2012. The detection of HPV infection was performed using the hybrid capture and the genotyping was by PCR (HPV 6, 11, 16, 18, 30, 31, 33, 35, 45, 51, and 52). 36% of women were HPV-positive and the most prevalent genotypes were HPV 51, 52, 16, and 33 (42, 38, 37, and 34%, respectively). The prevalence of co-infection was higher (75.37%) than mono-infection in women HPV positives. All genotypes were co-infected with HPV 16, but the co-infection with 51–52 genotypes was the most frequent combination in all cases. The co-infection was very common; each HPV genotype showed different preferences for co-infection with other genotypes, HPV 51–52 co-infection was the most frequent. The HPV 16, 33, 51 and 52 were the most prevalent and are a public health concern to the Mexican population.

1 November 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
SCSilvia Lorenia Cruz
Silvia Lorenia Cruz
ESElizabeth Sánchez-Miranda
Elizabeth Sánchez-Miranda
JCJorge Ivan Castillo-Arellano
Jorge Ivan Castillo-Arellano
Rodolfo Daniel Cervantes-VillagranaRodolfo Daniel Cervantes-Villagrana
Rodolfo Daniel Cervantes-Villagrana
AIAlfredo Ibarra-Sánchez
Alfredo Ibarra-Sánchez
CGClaudia González-Espinosa
Claudia González-Espinosa